RESUMEN
Our prospective, randomised controlled study was to assess the role of oral pyridoxine (Vitamin B6) supplementation in addition to standard dietary advice, compared against only dietary advice, in the reduction of urinary oxalate levels in patients with urinary calculi along with proven hyperoxaluria. 74 subjects were randomly divided into Interventional Group (n=38) who received oral Pyridoxine 40mg/day with dietary oxalate restriction and Control Group (n=36) who received only dietary oxalate restriction. Both groups were evaluated and statistically compared at the end of 3 months. Interventional group showed statistically significant (p = 0.0001) reduction in 24 hours urinary oxalate levels. Pyridoxine, cofactor in the alanine–glyoxalate–transaminase pathway converts glyoxalate to glycine and reduces oxalate production thereby decreasing hyperoxaluria, risk factor of urolithiasis. Oral Pyridoxine supplementation (40 mg/day) with dietary oxalate restriction can be a prophylactic measure for prevention of recurrence of calcium oxalate urolithiasis.